NZOZ LECZNICA MAK-MED s.c.

The site expands its inflammatory disease expertise to ocular health, exploring new treatments for ocular inflammation and related eye conditions.

• Investigation of biologic agents for uveitis
• Evaluation of systemic immunomodulator safety on eye health
• Pilot study of topical therapy for inflammatory eye disease

NZOZ LECZNICA MAK-MED s.c. integrates eye‑focused research within its broader autoimmune portfolio.

Trials concentrate on systemic autoimmunity, including systemic lupus erythematosus and Sjögren’s disease, to test innovative targeted therapies and improve disease control.

• Novel JAK inhibitor study for systemic lupus erythematosus
• Combination biologic approach in Sjögren’s disease
• Safety profiling of immune modulators across autoimmune disorders

The research team at NZOZ LECZNICA MAK-MED s.c. aims to broaden therapeutic options for patients with immune‑mediated diseases.

A robust program addresses inflammatory joint disorders such as rheumatoid arthritis and psoriatic arthritis, as well as degenerative knee disease, evaluating efficacy of new biologics and oral agents.

• Efficacy assessment of new biologics in rheumatoid arthritis
• Biosimilar versus reference product comparison for joint disease
• Pain‑reduction outcomes in participants with knee osteoarthritis
• Long‑term safety of anti‑TNF therapy in psoriatic arthritis

NZOZ LECZNICA MAK-MED s.c. leverages its expertise to advance treatment options for musculoskeletal conditions.

Research focuses on weight management and metabolic health, particularly in individuals with obesity and comorbid joint disease, to determine how weight loss influences symptom severity.

• Weight‑loss intervention trial using obesity as primary endpoint
• Diet‑exercise adjunct study on knee pain in obese participants
• Metabolic profiling of subjects receiving novel oral agents

The centre’s metabolic studies complement its broader autoimmune and musculoskeletal research agenda.

Ongoing investigations target chronic skin disorders such as plaque psoriasis, testing new biologics to reduce lesions and improve patient quality of life.

• Phase III evaluation of oral therapy for plaque psoriasis
• Biosimilar comparison for psoriasis severity scoring
• Long‑term safety of subcutaneous treatment in severe skin disease
• Efficacy of IL‑23 inhibition in moderate to severe psoriasis

NZOZ LECZNICA MAK-MED s.c. strives to bring innovative skin‑focused therapies to market.

Emerging projects explore how systemic immunomodulators affect oral health, including salivary gland function and mucosal healing.

• Observational study of salivary gland function under immune modulators
• Assessment of oral mucosal recovery with biologic therapy
• Safety monitoring of dental health during systemic trial participation

The site’s expanding portfolio now incorporates stomatognathic research to address comprehensive patient wellbeing.